Loading...

GB Sciences, Inc.

GBLX•PNK
HealthcareBiotechnology
$0.00
$0.00(0.00%)

GB Sciences, Inc. (GBLX) Stock Overview

Explore GB Sciences, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for GBLXStats details for GBLX are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for GBLXAnalyst Recommendations details for GBLX are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

GB Sciences, Inc. engages in the research and development of plant-based medicines in North America and Europe. The company offers cannabinoid-inspired medicines and complex therapeutic mixtures for the prescription drug market. Its intellectual property covers a range of conditions and programs in pre-clinical animal stage for Parkinson's disease, neuropathic pain, chronic pain, COVID-related cytokine release syndrome, depression/anxiety, and cardiovascular therapeutic programs. The company was formerly known as Growblox Sciences, Inc. and changed its name to GB Sciences, Inc. in October 2016. GB Sciences, Inc. was incorporated in 2001 and is based in Las Vegas, Nevada.

CEO

Dr. Andrea Small-Howard M.B.A., MBA, Ph.D.

Employees

2

Headquarters

3550 West Teco Avenue, Las Vegas, NV

Founded

2008

Frequently Asked Questions